Department of Neurology, Ulm University, 89081, Ulm, Germany.
CHDI Foundation, Princeton, NJ, 08540, USA.
Genome Biol. 2022 Sep 7;23(1):189. doi: 10.1186/s13059-022-02752-5.
A major challenge in neurodegenerative diseases concerns identifying biological disease signatures that track with disease progression or respond to an intervention. Several clinical trials in Huntington disease (HD), an inherited, progressive neurodegenerative disease, are currently ongoing. Therefore, we examine whether peripheral tissues can serve as a source of readily accessible biological signatures at the RNA and protein level in HD patients.
We generate large, high-quality human datasets from skeletal muscle, skin and adipose tissue to probe molecular changes in human premanifest and early manifest HD patients-those most likely involved in clinical trials. The analysis of the transcriptomics and proteomics data shows robust, stage-dependent dysregulation. Gene ontology analysis confirms the involvement of inflammation and energy metabolism in peripheral HD pathogenesis. Furthermore, we observe changes in the homeostasis of extracellular vesicles, where we find consistent changes of genes and proteins involved in this process. In-depth single nucleotide polymorphism data across the HTT gene are derived from the generated primary cell lines.
Our 'omics data document the involvement of inflammation, energy metabolism, and extracellular vesicle homeostasis. This demonstrates the potential to identify biological signatures from peripheral tissues in HD suitable as biomarkers in clinical trials. The generated data, complemented by the primary cell lines established from peripheral tissues, and a large panel of iPSC lines that can serve as human models of HD are a valuable and unique resource to advance the current understanding of molecular mechanisms driving HD pathogenesis.
神经退行性疾病的一个主要挑战是确定能够跟踪疾病进展或对干预措施做出反应的生物疾病特征。目前正在进行几项亨廷顿病(HD)的临床试验,HD 是一种遗传性、进行性神经退行性疾病。因此,我们研究了外周组织是否可以作为 HD 患者在 RNA 和蛋白质水平上易于获得的生物标志物的来源。
我们从骨骼肌、皮肤和脂肪组织中生成了大量高质量的人类数据集,以探究人类无症状前和早期 HD 患者的分子变化——这些患者最有可能参与临床试验。转录组学和蛋白质组学数据分析显示出稳健的、与疾病阶段相关的失调。基因本体分析证实了炎症和能量代谢在周围 HD 发病机制中的参与。此外,我们观察到细胞外囊泡内稳态的变化,其中我们发现了涉及该过程的基因和蛋白质的一致变化。从生成的原代细胞系中获得了横跨 HTT 基因的深入单核苷酸多态性数据。
我们的“组学”数据记录了炎症、能量代谢和细胞外囊泡内稳态的参与。这表明有可能从 HD 的外周组织中识别出适合临床试验的生物标志物的生物标志物。生成的数据,辅以从外周组织建立的原代细胞系和大量可作为 HD 人类模型的 iPSC 系,是推进当前对驱动 HD 发病机制的分子机制的理解的宝贵而独特的资源。